šŸŽ‰ Wishing our readers, advertisers and collaborators a purposeful and prosperous 2026. Thank you for being part of our journey as we continue to inform, inspire and build impact together in the year ahead. šŸŽ‰ šŸŽ‰ Wishing our readers, advertisers and collaborators a purposeful and prosperous 2026. Thank you for being part of our journey as we continue to inform, inspire and build impact together in the year ahead. šŸŽ‰
Insilico Medicine partners with EQRx for AI-driven drug discovery

Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, has entered i...

March 25, 2022 | Friday | News
Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments

Biogen Inc. and Eisai Co., Ltd. announced that the companies have amended their existing collaboration agreement on aduc...

March 21, 2022 | Monday | News
RedHill inks deal worth $6M with Kukbo for COVID-19 drug in South Korea

RedHill Biopharma has entered into an exclusive license agreement with Kukbo Co., a South Korean corporation, for o...

March 16, 2022 | Wednesday | News
Astellas’ menopause drug fails in Asia trial

Japan-based Astellas Pharma Inc. has announced topline results from the ongoing Phase 3 MOONLIGHT 1 clinical trial inves...

March 16, 2022 | Wednesday | News
China approves SCG's T Cell Therapy IND to treat Hepatitis B virus

Singapore-based SCG Cell Therapy Pte Ltd, a leading biotechnology company,  announced that the China National Medic...

March 14, 2022 | Monday | News
China's Gan & Lee Pharma begins first-in-human trial for diabetes drug

Chinese firm Gan & Lee Pharmaceuticals has announced that the first subject has been dosed in our Phase I, double-bl...

March 11, 2022 | Friday | News
Dr Andreas Amrein joins Advanced Clinical to lead global development and expansion in APAC

Advanced Clinical, a clinical development and strategic resourcing organization committed to providing a better clinical...

March 10, 2022 | Thursday | News
China approves phase II trial of Akeso's cancer drug

Akeso, Inc., a biopharmaceutical company dedicated to the development of innovative antibody drugs, has announced that t...

March 8, 2022 | Tuesday | News
I-Mab receives FDA orphan drug designation for cancer drug

China based I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializa...

March 4, 2022 | Friday | News
China-based startup InxMed raises $50 M in Series B Financing

InxMed Co., Ltd, a clinical-stage biotechnology startup based in China, has announced that it had completed $5...

March 4, 2022 | Friday | News
China's Adagene partners with French firm Sanofi for Immuno-Oncology

China's Adagene,  a company transforming the discovery and development of antibody-based therapies, has announced a...

March 3, 2022 | Thursday | News
China approves Phase II clinical trial of InnoCare's cancer drug

InnoCare Pharma, a leading biopharmaceutical company, has announced the Investigational New Drug (IND) approval of its B...

March 3, 2022 | Thursday | News
China-based Fosun Pharma and Insilico Medicine advance AI-driven drug discovery

Shanghai Fosun Pharmaceutical (Group) Co. and Insilico Medicine have entered into a collaboration agreement to advance t...

January 12, 2022 | Wednesday | News
Taiwan's GoldenBiotech suggests 100% recovery with oral drug Antroquinonol in COVID-19 patients

Golden Biotechnology Corp., a leading Taiwanese biopharmaceutical company, has announced that its Phase 2 COVID-19 trial...

January 10, 2022 | Monday | News
Korean startup Astrogen to use AI for drug design against Parkinson’s Disease

South Korea-based startup Astrogen and Paris-based firm Iktos have announced a research collaboration to use A...

January 6, 2022 | Thursday | News
Japan's PRISM BioLab partners with Roche and Genentech for drug discovery research

PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery ...

January 5, 2022 | Wednesday | News
China’s BeiGene expands collaboration with Novartis for oncology medicines

China-based BeiGene has announced an option, collaboration and license agreement with Novartis Pharma AG to develop, man...

December 28, 2021 | Tuesday | News
Merck and Ridgeback’s COVID-19 pill receives ā€˜special approval’ in Japan

Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics have announced that Japan’...

December 27, 2021 | Monday | News